合成渗透性宫颈扩张器与地诺前列酮阴道栓用于引产的随机试验
该开放标签优效性随机对照试验在4家英格兰医院纳入674名≥37周单胎头位胎膜完整引产孕妇,比较Dilapan-S与地诺前列酮。Dilapan-S组阴道分娩失败率37.4%,地诺前列酮组34.3%,调整后风险差0.02(95%CI -0.05至0.10),母婴不良事件相似。
要点
- Dilapan-S组阴道分娩失败或剖宫产率为37.4%,地诺前列酮组为34.3%,调整后风险差0.02(95%CI -0.05至0.10)。
- 两组母婴不良事件相似。
- 试验因COVID-19研究限制未达到计划样本量860人。
核心结论
- 使用Dilapan-S引产的女性剖宫产率及母婴不良事件与地诺前列酮相似。
研究设计与样本
- 开放标签优效性随机对照试验,在4家英格兰医院进行。
- 纳入≥16岁、≥37周妊娠、单胎头位、胎膜完整需引产的女性。
- 采用电话随机系统按医院、产次、体重指数和母亲年龄最小化随机分配至Dilapan-S或地诺前列酮。
- 共随机674名女性(Dilapan-S组337名,地诺前列酮组337名),因COVID-19研究限制未达到计划样本量860名。
- 主要结局为未能实现阴道分娩(即剖宫产),按意向性分析并尽可能调整设计变量。
主要发现
- Dilapan-S组126名(37.4%)发生未能阴道分娩或剖宫产,地诺前列酮组115名(34.3%)发生,调整后风险差0.02(95%CI -0.05至0.10)。
- 两组母婴不良事件相似。
- 地诺前列酮组有2名女性主要结局数据缺失。
关键数值与推荐
- 主要结局:未能实现阴道分娩(即剖宫产)在Dilapan-S组为37.4%(126/337),地诺前列酮组为34.3%(115/337),调整后风险差0.02(95%CI -0.05至0.10)。
- 次要结局包括母婴不良事件,两组相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 试验因COVID-19大流行期间的研究限制未达到计划样本量860名参与者。
- 地诺前列酮组有2名女性主要结局数据缺失。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Induction of labor is a commonly performed obstetrical intervention. Vaginal prostaglandin E2 (dinoprostone) is a first-choice agent. Mechanical methods of induction are slower in achieving cervical ripening but have a lower risk of adverse effects. OBJECTIVE: This study aimed to compare the efficacy, maternal and neonatal safety, and maternal satisfaction of a synthetic osmotic cervical dilator (Dilapan-S) with those of dinoprostone. STUDY DESIGN: This was an open-label superiority randomized controlled trial in 4 English hospitals. Eligible participants were women ≥16 years of age undergoing induction of labor for a singleton pregnancy at ≥37 weeks' gestation with vertex presentation and intact membranes. The women were randomly assigned to receive either Dilapan-S or dinoprostone using a telephone randomization system minimized by hospital, parity, body mass index, and maternal age. The induction agent was replaced as required until the cervix was assessed as favorable for labor by the Bishop score. The primary outcome was failure to achieve vaginal delivery (ieor a cesarean delivery being performed). The secondary outcome measures included maternal and neonatal adverse events. Analysis was by intention-to-treat, adjusting for design variables where possible. RESULTS: Between December 19, 2017 and January 26, 2021, 674 women were randomized (337 to Dilapan-S, and 337 to dinoprostone). The trial did not reach its planned sample size of 860 participants because of restrictions on research during the COVID-19 pandemic. The primary outcome was missing for 2 women in the dinoprostone group. Failure to achieve vaginal delivery (or a cesarean delivery being performed) occurred in 126 women (37.4%) allocated to Dilapan-S and in 115 (34.3%) women allocated to dinoprostone (adjusted risk difference, 0.02; 95% confidence interval, -0.05 to 0.10). There were similar maternal and neonatal adverse events between the groups. CONCLUSION: Women undergoing induction of labor with Dilapan-S have similar rates of cesarean delivery and maternal and neonatal adverse events compared with dinoprostone.
引用
- Gupta JK, Maher A, Stubbs C, et al. A randomized trial of synthetic osmotic cervical dilator for induction of labor vs dinoprostone vaginal insert. Am J Obstet Gynecol MFM. 2022. PMID: 35358740. doi:10.1016/j.ajogmf.2022.100628
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。